Effect of ovarian suppression with gonadotropin-releasing hormone agonist on glucose disposal and insulin secretion by Toth, Michael J. et al.
 doi:10.1152/ajpendo.00789.2007 
 294:1035-1045, 2008. First published Apr 15, 2008;Am J Physiol Endocrinol Metab
Matthews and Peter R. Casson 
Michael J. Toth, Brian C. Cooper, Richard E. Pratley, Andrea Mari, Dwight E.
 You might find this additional information useful...
59 articles, 35 of which you can access free at: This article cites 
 http://ajpendo.physiology.org/cgi/content/full/294/6/E1035#BIBL
including high-resolution figures, can be found at: Updated information and services 
 http://ajpendo.physiology.org/cgi/content/full/294/6/E1035
 can be found at: AJP - Endocrinology and Metabolismabout Additional material and information 
 http://www.the-aps.org/publications/ajpendo
This information is current as of October 14, 2009 . 
  
 http://www.the-aps.org/.
20814-3991. Copyright © 2005 by the American Physiological Society. ISSN: 0193-1849, ESSN: 1522-1555. Visit our website at 
organization. It is published 12 times a year (monthly) by the American Physiological Society, 9650 Rockville Pike, Bethesda MD 
 publishes results of original studies about endocrine and metabolic systems on any level ofAJP - Endocrinology and Metabolism
 o
n
 O
ctober 14, 2009 
ajpendo.physiology.org
D
ow
nloaded from
 
Effect of ovarian suppression with gonadotropin-releasing hormone agonist
on glucose disposal and insulin secretion
Michael J. Toth, Brian C. Cooper, Richard E. Pratley, Andrea Mari, Dwight E. Matthews,
and Peter R. Casson
Departments of Medicine and Obstetrics and Gynecology, University of Vermont, Burlington, Vermont, and Institute
of Biomedical Engineering, National Research Council, Padua, Italy
Submitted 19 December 2007; accepted in final form 10 April 2008
Toth MJ, Cooper BC, Pratley RE, Mari A, Matthews DE,
Casson PR. Effect of ovarian suppression with gonadotropin-releas-
ing hormone agonist on glucose disposal and insulin secretion. Am J
Physiol Endocrinol Metab 294: E1035–E1045, 2008. First published
April 15, 2008; doi:10.1152/ajpendo.00789.2007.—Several lines of
evidence suggest that ovarian hormones influence glucose homeosta-
sis, although their exact role in humans has not been clearly defined.
In the present study, we sought to test the hypothesis that ovarian
hormones regulate glucose homeostasis by examining the effect of
pharmacologically induced ovarian hormone deficiency on glucose
disposal and insulin secretion. Young, healthy women with regular
menstrual patterns were studied during the follicular and luteal phases
of their cycle at baseline and after 2 mo of treatment with gonado-
tropin-releasing hormone agonist (GnRHa; n  7) or placebo (n  6).
Using hyperglycemic clamps, in combination with stable isotope-
labeled (i.e., 13C and 2H) glucose tracers, we measured glucose
disposal and insulin secretion. Additionally, we assessed body com-
position and regional fat distribution using radiologic imaging tech-
niques as well as glucoregulatory hormones. Ovarian hormone sup-
pression with GnRHa did not alter body composition, abdominal fat
distribution, or thigh tissue composition. There was no effect of
ovarian suppression on total, oxidative, or nonoxidative glucose
disposal expressed relative to plasma insulin level. Similarly, no effect
of ovarian hormone deficiency was observed on first- or second-phase
insulin secretion or insulin clearance. Finally, ovarian hormone defi-
ciency was associated with an increase in circulating adiponectin
levels but no change in leptin concentration. Our findings suggest that
a brief period of ovarian hormone deficiency in young, healthy,
eugonadal women does not alter glucose disposal index or insulin
secretion, supporting the conclusion that ovarian hormones play a
minimal role in regulating glucose homeostasis. Our data do, how-
ever, support a role for ovarian hormones in the regulation of plasma
adiponectin levels.
TISSUE INSULIN SENSITIVITY and pancreatic -cell responsiveness
decrease with age (1, 25), contributing to worsening glucose
tolerance and, in some individuals, development of type 2
diabetes. In women, these age-related changes may accelerate
following menopause (30, 37, 56, 57), leading to the hypoth-
esis that ovarian hormone deficiency impairs insulin secretion
and/or action. Supporting this notion are studies demonstrating
that replacement of ovarian hormones in postmenopausal
women enhances glucoregulation (4, 10, 18, 29, 30, 54). In
fact, large clinical trials have shown that postmenopausal
hormone replacement reduces the risk of developing diabetes
(26, 31, 41). Collectively, these findings suggest that ovarian
hormones regulate glucose homeostasis in a manner that may
confer protection against the subsequent development of dia-
betes.
There is a considerable amount of evidence, however, that
contradicts this conclusion. For instance, some investigations
comparing pre- and postmenopausal women have found no
differences in insulin sensitivity (47) or greater insulin sensi-
tivity in postmenopausal women (56). Moreover, other studies
have shown either no effect or deleterious effects of ovarian
hormone replacement therapy on glucose homeostasis in post-
menopausal women (17, 21, 42, 43, 53, 55) that is corrected
upon cessation of therapy (43). Finally, studies performed at
different times of the menstrual cycle that correspond with
relative ovarian hormone deficiency and excess have suggested
detrimental effects of ovarian hormones on glucose homeosta-
sis (13, 38, 50). The reason(s) for differing results among
studies are not clear but probably relate to the variety of
experimental paradigms employed, the nature of the hormonal
stimulus (e.g., endogenous vs. exogenous), and differences in
the populations studied with respect to age, adiposity, activity
level, and other factors. Regardless of an explanation for these
disparities, on balance there is no clear consensus that emerges
regarding the role of ovarian hormones in the regulation of
glucose homeostasis.
The primary goal of this study was to examine the role of
ovarian hormones in the regulation of glucose disposal and
insulin secretion. To accomplish this objective, we studied
young, healthy, nonobese women with normal menstrual cy-
clicity before and after 2 mo of treatment with gonadotropin-
releasing hormone agonist (GnRHa) or placebo. GnRHa ad-
ministration downregulates the production and release from the
pituitary of luteinizing hormone and follicle-stimulating hor-
mone, rapidly inducing a state of hypogonadotropic hypogo-
nadism with consequent reductions in ovarian hormones to
postmenopausal levels. This experimental paradigm provides
the unique opportunity of studying the effects of ovarian
hormone deficiency by use of a within-subjects design. We
chose a short treatment period of 2 mo to minimize the effects
of ovarian hormone deficiency on other physiological/meta-
bolic systems, such as blood flow (8) or adiposity (49), that
might confound our ability to detect an effect of the hormones
on glucose homeostasis. Insulin secretion and clearance and
intracellular pathways of glucose disposal were measured dur-
ing hyperglycemic clamps from insulin and C-peptide levels,
stable isotope-labeled glucose tracer kinetics, and indirect
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calorimetry. We hypothesized that ovarian hormone suppres-
sion with GnRHa would reduce glucose disposal by decreasing
flux through the nonoxidative pathway and decrease insulin
secretion. In addition, to examine whether ovarian suppression
might influence glucose homeostasis through modulation of
other hormonal systems, we assessed the effect of GnRHa
administration on concentrations of circulating leptin and adi-
ponectin, glucoregulatory hormones that are thought to be
influenced, in part, by sex steroids (20, 24).
MATERIALS AND METHODS
Materials. D-[U-13C]glucose (98% 13C), D-[6,6-2H2]glucose (98%
13C), and sodium [13C]bicarbonate (99% 13C) were obtained from
Cambridge Isotope Laboratories (Andover, MA). Leuprolide acetate
(Lupron Depot; 3.75 mg) was obtained from TAP Pharmaceuticals
(Lake Forest, IL).
Subjects. Fourteen healthy young women were recruited and 13
women, ranging in age from 22 to 37 yr (mean  SE; 29  1 yr),
completed the study. Women were nonobese (BMI 28 kg/m2;
23.4  0.8 kg/m2), had a stable body weight (2 kg) for 6 mo prior
to study, were healthy on the basis of medical history, physical
examination, and routine blood tests, were glucose tolerant (glucose
7.77 mmol/l 2 h following a 75-g oral glucose load), had no history
of tobacco use, and were not on any medication that could affect
glucose metabolism or ovarian/reproductive function. None of the
volunteers had been exposed to any form of hormone-based contra-
ceptive therapy for at least 6 mo prior to study and reported having at
least two spontaneous cycles in the 3 mo prior to recruitment and a
cycle length of between 25 and 32 days. The nature, purpose, and
possible risks of the study were explained to each subject before she
gave written consent to participate. The experimental protocol was
approved by the Committee on Human Research at the University of
Vermont.
Experimental protocol. Each volunteer underwent an outpatient
screening visit at which time medical history, physical examination,
biochemical laboratory tests, an exercise stress test, and an oral
glucose tolerance test were performed. Volunteers that met the eligi-
bility criteria were randomized using a stratified (age and BMI) block
approach to receive the GnRHa leuprolide acetate (n  7; Lupron
Depot; 3.75 mg im; 28  2 yr) or placebo (n  7; 0.9% saline; 30 
2; P  0.439). Prior to study, each volunteer’s menstrual cycle was
monitored for at least two cycles using menstrual diaries, ovulation
prediction kits (Ovu-Quick One-Step; Quidel, San Diego, CA) and
midluteal phase blood draws to discern length of the cycle and
follicular and luteal phases.
Each woman underwent metabolic testing on three occasions: two
prior to treatment and one following treatment. Baseline testing
occurred during the early- to midfollicular phase (cycle days 3–8) and
during the midluteal phase (cycle days 19–25). The order of baseline
metabolic testing with respect to cycle phase (follicular-luteal or
luteal-follicular) was randomized. Following baseline testing, GnRHa
or placebo was administered by intramuscular injection during the
midluteal phase. On average, the second injection was given 30 days
following the first injection in the GnRHa group and 29 days follow-
ing the first injection in the placebo group. Posttreatment metabolic
testing was performed on average 56 days following the first injection
in the GnRHa group and 58 days following the first injection in the
placebo group. Posttreatment testing in the placebo group was per-
formed during the same phase of the cycle as the second baseline
testing period. Women in the placebo group underwent evaluations in
one of two testing orders: follicular-luteal-luteal or luteal-follicular-
follicular. Thus, posttreatment testing was randomized in volunteers
in the placebo group in accordance with baseline testing order.
Directly preceding each bout of metabolic testing, volunteers were
provided 3 days of a weight maintenance, standardized diet (20%
protein, 25% fat, and 55% carbohydrate) by the General Clinical
Research Center (GCRC) Metabolic Kitchen. The diet was designed
to provide at least 1 g protein/kg body wt and 200 g carbohydrate/day
and was identical for each bout of testing.
Insulin secretion and glucose metabolism measurements were per-
formed under hyperglycemic conditions the morning following an
overnight visit to the GCRC. Volunteers were fasted after 1900 the
evening of admission. At 0600, catheters were placed in an ante-
cubital vein for infusion and retrograde in a dorsal hand vein for blood
draws. Baseline blood and breath samples were taken and primed
(3.46 and 0.131 mg/kg), continuous (0.048 mg kg1 min1 and 1.82
g kg1 min1) infusions of [6,6-2H2]- and [U-13C]glucose were
started and maintained for 240 min. The bicarbonate pool was primed
(10.6 mol/kg) with sodium [13C]bicarbonate. At 120 min, a variable-
rate priming dose of 20% dextrose was started (from 120 to 140 min),
followed by a variable rate infusion (from 140 to 240 min), with the
goal of obtaining a steady-state plasma glucose level of 125 mg/dl
above fasting glucose level. Both [6,6-2H2]- and [U-13C]glucose were
added to the 20% dextrose infusate prior to the study to preserve
steady-state plasma enrichments. Plasma glucose level was monitored
every 2 min during the first 20 min of the clamp and every 5 min
thereafter, and the dextrose infusion rate was adjusted to achieve the
hyperglycemic target. All infusions were stopped at 240 min except
for the dextrose infusion, which was continued and tapered until no
longer required to maintain normal glycemia. Problems with intrave-
nous access in one patient in the placebo group during luteal phase
and posttreatment testing rendered portions or all of her clamp study
data unusable for analysis. Because of this, the final sample sizes were
n  6 for placebo and n  7 for GnRHa for all analyses.
Blood and breath samples were drawn at 90, 100, 110, and 120 min
for measurement of basal and at 210, 220, 230, and 240 min for
measurement of clamp glucose kinetics. Blood samples were drawn at
2-min intervals from 120 to 140 min and then at 15-min intervals
thereafter for the determination of plasma insulin and C-peptide
levels. Oxygen consumption and carbon dioxide production rates were
determined at 60 and 210 min, using the ventilated hood technique
(DeltaTrac, Yorba Linda, CA). Oxygen consumption data were not
available on two volunteers during the baseline clamp measurements
(one during follicular- and one during luteal-phase evaluation) be-
cause of technical problems.
Body composition. Body mass was measured on a metabolic scale
(Scale-Tronix, Wheaton, IL). Fat mass, fat-free mass, and bone
mineral mass were each measured by dual-energy X-ray absorptiom-
etry using a GE Lunar Prodigy densitometer (GE Lunar, Madison,
WI). Bone mineral mass data are not presented.
Computed tomography. Abdominal adipose tissue areas and
midthigh fat and muscle areas were measured by computed tomogra-
phy with a Phillips Brilliance 40 or 64 computed tomography scanner
(Phillips Medical Systems, Cleveland, OH), as described previously
(48). For the midthigh scan, the midpoint between the anterior
superior illiac crest and the proximal aspect of the patella was
measured using external landmarks and the midpoint marked on the
patients thigh. For all scans, the mark for the midthigh scan was
placed at the same point. Images from these scans were analyzed
using NIH Image software (Image J 1.36b) to determine adipose tissue
and muscle areas, as described previously (48). Midthigh tissue
composition measurements were not performed in two patients (one in
each group) posttreatment because of logistical problems.
Analytic methods. Serum insulin was measured by radioimmuno-
assay (Linco, St. Louis, MO). The intra- and interassay coefficients of
variation (CV) for insulin were 3.2 and 4%, respectively. Plasma
C-peptide levels were determined by radioimmunoassay (Linco). The
intra- and interassay CV were 4.6 and 4.9%, respectively. Plasma
glucose concentrations were measured by a glucose analyzer (Yellow
Springs Instruments, Yellow Springs, OH).
Plasma [6,6-2H2]glucose enrichment was measured by electron
impact ionization gas chromatography-mass spectrometry (model
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5971A; Hewlett-Packard, Palo Alto, CA), as described previously
(19). Prior to measurement, glucose was derivatized to the butylbor-
onate acetate derivative. Injections of butylboronate acetyl glucose
were made isothermally while monitoring the [M-57] ions at a
mass-to-charge ratio (m/z) of 297 and 299 for unlabeled and [6,6-
2H2]glucose, respectively.
For plasma glucose 13C measurements, following precipitation and
removal of plasma proteins, the methylboronate glucose derivative
was prepared (52) as described previously (23). The methylboronate
acetate glucose derivatives were measured for 13C content by gas
chromatography-combustion-isotope ratio mass spectrometry (23) us-
ing a DELTA-Plus instrument with a GCC-III unit (Thermo-Fisher
Finnigan, Bremen, Germany), and these data were transformed into
mole fraction abundance of 13C as described (23). Enrichment of 13C
was calculated as the difference between the F13C of the sample minus
the F13C of a baseline sample taken prior to administration of the
isotope and was adjusted for the number of carbons added to the
glucose by the derivatization procedure.
The enrichment of expired CO2 was measured by isotope ratio mass
spectrometry (PDZ Europa 20/20 ABCA-NT; Crewe, Cheshire, UK).
Calculations. Glucose tracers were used in this study to monitor
endogenous glucose production ([6,6-2H2]glucose) and glucose oxi-
dation ([U-13C]glucose). The following section details calculations
used to derive these two estimates from tracer kinetic data.
The rate of appearance of glucose (Ra) can be calculated from the
[6,6-2H2] tracer as
Ra i	Ei/Ep 1
 (1)
where i is the rate of the 6,6-2H2 tracer infusion, Ei is the enrichment of
the glucose tracer in the infusate, and Ep is the mean enrichment of the
glucose tracer in plasma. During the hyperglycemic clamp, the equation
above must be modified to account for the fact that the glucose tracer was
infused into the body from two sources: the [6,6-2H2]glucose tracer
infusion and the 20% dextrose infusion. Thus, the glucose Ra during the
clamp (Ra 2H) from the [6,6-2H2]glucose tracer is calculated as
Ra 2H 	Ei Ep
  i 	Ei Dex Ep clamp
  iDex/Ep clamp (2)
where i, Ei, and Ep are as defined above, Ei DEX is the enrichment of
[6,6-2H2]glucose in the 20% dextrose infusate, Ep clamp is the enrich-
ment of the tracer in the plasma, and iDEX is the infusion rate of the
20% dextrose. The glucose Ra data derived from the [6,6-2H2]glucose
tracer during the clamp was used to determine endogenous glucose
production during the clamp. Total glucose disposal during the clamp
was calculated from data collected during 210–240 min as the 20%
dextrose infusion rate plus the Ra 2H from the [6,6-2H2]glucose tracer.
Total glucose disposal was then expressed relative to plasma insulin
concentration during the same time period and is referred to as the
glucose disposal index.
Using the [U-13C]glucose tracer, we partitioned glucose disposal
into oxidative and nonoxidative pathways. To accomplish this, the
fraction of [U-13C]glucose tracer infused that was oxidized during the
last 30 min of the hyperglycemic clamp (fox clamp) was calculated as
fox clamp F13CO2 clamp/i13C  6 (3)
where F13CO2 clamp is the rate of 13CO2 excretion calculated as the
breath 13CO2 enrichment times the CO2 production rate derived from
indirect calorimetry, i13C is the infusion rate of the 13C from the
[U-13C]glucose tracer and 20% dextrose infusate, and 6 is a constant
that accounts for the fact that there are 6 13C labels in the [U-13C]glu-
cose tracer. The bicarbonate retention factor for the 13C tracer was
assumed to be 1.0 during the hyperglycemic clamp. The fox clamp was
then multiplied by the Ra for the [U-13C]glucose tracer (Ra 13C) to
derive the rate of glucose oxidation during the clamp. Ra 13C was
calculated as
Ra 13C 	i13C  Ei 13C
 	iDex  EDex
/Ep 13C (4)
where i13C is the infusion rate of the [U-13C6]glucose tracer, Ei 13C is the
enrichment of the [U-13C6]glucose infusate, iDEX is as defined above,
EDEX is the enrichment of the [U-13C6]glucose in the 20% dextrose
infusate, and Ep 13C is the plasma enrichment of [U-13C6]glucose. As
with total glucose disposal, oxidative and nonoxidative disposal were
expressed relative to plasma insulin levels.
Insulin secretion was calculated by deconvolution according to the
method of van Cauter et al. (51), using C-peptide concentrations.
First-phase insulin secretion was defined from 120 to 128 min and
second-phase secretion from 128 to 240 min and is expressed as the
area under the curve during these time periods. Insulin clearance was
calculated as the ratio of insulin secretion rate to the corresponding
plasma insulin concentration from 140 to 240 min and is expressed as
the mean of the ratios at each time point.
Hormone measurements. Serum levels of estrone, estradiol, testos-
terone, androstenedione, and dehydroepiandrosterone were measured
by radioimmunoassay. Prior to measurement, steroids were extracted
from serum with hexane-ethyl acetate (3:2). Androstenedione, dehy-
droepiandrosterone (DHEA), and testosterone were then separated by
Celite column partition chromatography using increasing concentra-
tions of toluene in trimethylpentane. Estrone and estradiol were
separated in a similar fashion using ethyl acetate in trimethylpentane.
Dehydroepiandrosterone sulfate (DHEA-S) and sex hormone-binding
globulin were measured by direct chemiluminescence immunoassays
using the Immulite analyzer (Diagnostic Products, Inglewood, CA).
Free estradiol and testosterone were calculated using their respective
total serum concentration, sex hormone-binding globulin levels, and
an assumed constant for albumin in a validated algorithm (44). Intra-
and interassay CV for steroid hormones and their binding proteins
varied from 4 to 8 and from 8 to 13%, respectively. The limit of
detection for each hormone was as follows: estrone: 4 pg/ml; estra-
diol: 3 pg/ml; testosterone: 15 pg/ml; DHEA: 30 pg/ml; DHEA-S: 30
ng/ml; androstenedione: 30 pg/ml; sex hormone-binding globulin: 0.2
nmol/l. Plasma leptin was measured by ELISA (Linco). The intra- and
interassay CV for leptin were 5 and 4.9%, respectively. Plasma
adiponectin levels were determined by ELISA (R&D Systems, Min-
neapolis, MN). This assay detects total plasma adiponectin levels,
which includes, but does not distinguish between, all molecular
weight species. The interassay CV ranges from 9 to 13%.
Statistics. Paired t-tests were used to compare data between base-
line follicular and luteal phase measurements in the entire cohort. For
comparison with posttreatment data, follicular and luteal phase mea-
surements were averaged and are referred to as “baseline” values. A
2  2 repeated-measures analysis of variance (RM-ANOVA) model
was used with treatment group (GnRHa vs. placebo) as the between-
subjects factor and time (baseline vs. posttreatment values) as the
within-subjects factor. If a significant group  time interaction effect
was found, a post hoc analysis was performed to assess the unique
effect of time within each group through an analysis of the simple
effects. For steroid hormone data, several variables (estrone, estradiol,
testosterone) were not normally distributed (Shapiro-Wilk test, P 
0.05) and remained so after attempts at transformation (e.g., log10).
Thus, we evaluated the normality of the distribution of the difference
in steroid hormone data between baseline and posttreatment evalua-
tions. For all calculated differences, the assumption of normality was
fulfilled. Thus, the calculated difference was compared between
groups using an unpaired t-test. In addition, Wilcoxon signed rank
tests were used to test the difference of estrone and estradiol levels from
the each menstrual cycle phase at baseline to posttreatment. All analyses
were conducted with SPSS software (SPSS v. 15.0; Chicago, IL).
RESULTS
Baseline and posttreatment body composition and fat distri-
bution data are shown in Table 1. Comparing average baseline
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values between the two groups, women in the placebo group
tended (P  0.09) to weigh more than those in the GnRHa
group due to the fact that they tended (P  0.07) to be taller
(GnRHa 161  3 vs. placebo 171  3 cm). No differences
were found, however, in BMI (GnRHa 23.0  1.2 vs. placebo
23.9  1.3 kg/m2, P  0.64). Similarly, no differences were
found between GnRHa and placebo groups in any index of
whole body or regional composition at baseline. Groups were
similar at baseline for peak aerobic capacity on an absolute
basis (GnRHa 2.33  0.18 vs. placebo 2.45  0.22 l/min, P 
0.68) or when statistically adjusted for fat-free mass (GnRHa
2.43  0.17 vs. placebo 2.33  0.18 l/min, P  0.72).
Similarly, there was no effect of time on body mass in either
group when considered across all three evaluations (GnRHa
59.8  3.2 vs. 60.6  3.4 vs. 60.0  3.3 kg, P  0.81; placebo
69.3  3.4 vs. 69.1  3.6 vs. 69.6  3.8 kg, P  0.321, for
follicular, luteal, and posttreatment evaluations, respectively). Fi-
nally, comparing baseline and posttreatment data, no group 
time interaction effects were found for any whole body or regional
tissue composition measure.
As expected, there were differences in estrone (55  13 vs.
104  14 pg/ml, P  0.01) and estradiol (92  30 vs. 223 
27 pg/ml, P  0.01) levels between the follicular and luteal
phases of the cycle, respectively. All other hormone levels did
not differ significantly with menstrual cycle phase.
The effect of ovarian suppression on serum steroid levels
and binding proteins is shown in Table 2. Testosterone, free
testosterone, and androstenedione decreased with treatment in
the GnRHa group compared with placebo (P  0.05), whereas
other hormone levels were unaffected. Because estrone and
estradiol differed by menstrual cycle phase, we also evaluated
the difference between each hormone measured at follicular
and luteal phase evaluations compared with the posttreatment
evaluation. In the GnRHa group, posttreatment estrone and
estradiol levels were lower than either follicular- or luteal-
phase evaluations (P  0.05 for all). In the placebo group, no
difference was found between follicular and posttreatment
estrone and estradiol levels (P  0.917 for both), whereas
estrone level was lower posttreatment compared with luteal
phase (P  0.05), and estradiol level tended to be lower (P 
0.08). Importantly, ovarian suppression was confirmed in all
volunteers in the GnRHa group 10 days following the first
injection, as indicated by plasma estradiol level 50 pg/ml, and
was confirmed at posttreatment testing (range 4–15 pg/ml).
The effect of menstrual cycle phase on glycemia (top),
insulin (middle) and c-peptide (bottom) levels during the hy-
perglycemic clamp are shown for follicular and luteal phase
evaluations in Fig. 1. No effect of cycle phase was found on the
fasting glucose level [follicular (F) 76  1 vs. luteal (L) 76 
1 mg/dl, P  0.97], insulin (F: 9.4  1.2 vs. L: 9.2  1.0
U/ml, P  0.822) or C-peptide (F: 1.8  0.3 vs. L: 1.8  0.2
ng/ml, P  0.80) level. There was a small, but significant,
difference in average plasma glucose level during the final 30
min of the clamp (F: 197  1 vs. L: 192  2 mg/dl, P  0.01).
Glucose disposal indexes and insulin secretion data for
follicular and luteal phases of the menstrual cycle are shown in
Fig. 2. There was no effect of menstrual cycle phase on total
glucose disposal normalized to insulin level [F: 12.6  2.2 vs.
L: 12.0  1.6 (mg/min)/(U/ml), P  0.628] or when glucose
disposal was not normalized to insulin levels (F: 616  50 vs.
L: 684  63 mg/min, P  0.133). Similarly, there was no
effect of cycle phase on residual endogenous glucose produc-
tion [F: 0.41 0.16 vs. L: 0.40 0.17 (mg/min)/(U/ml), P
0.903], nonoxidative glucose disposal [F: 11.3  2.2 vs. L:
10.9 1.6 (mg/min)/(U/ml), P 0.748] or oxidative glucose
disposal [F: 1.8  0.5 vs. L: 1.5  0.2 (mg/min)/(U/ml), P 
0.402]. Expression of glucose disposal data relative to body
mass or fat-free mass yielded no differences between menstrual
cycle phases (data not shown). There was a 10% greater area
Table 2. Effect of GnRHa administration on steroid
hormone and binding protein levels
Baseline Posttreatment
GnRHa Placebo GnRHa Placebo
Estrone, pg/ml 6910 9224 192 6011
Estradiol, pg/ml 12915 19051 9.81.4 12228
Free estradiol, pg/ml 2.980.35 4.320.98 0.240.05 2.830.64
Testosterone, ng/dl 382 364 202* 348
Free testosterone, ng/dl 6.540.38 6.210.59 3.870.58* 6.151.47
DHEA, nmol/l 6.531.24 6.460.44 7.392.30 5.730.70
DHEA-S, g/dl 12325 11219 12428 9314
Androstenedione, ng/ml 1.370.05 1.270.11 0.720.11* 1.060.15
Sex hormone-binding
globulin, nmol/l 574 566 517 547
Data are means  SE. DHEA, dehydroepiandrosterone; DHEA-S, dehydro-
epiandrosterone sulfate. Sample sizes are n  7 for GnRHa and n  6 for
placebo. *P  0.05, change with treatment different between GnRHa and
placebo groups.
Table 1. Effect of GnRHa administration on total and regional body composition
Baseline Posttreatment
GnRHa Placebo GnRHa Placebo
Weight, kg 60.23.3 69.23.5 60.03.3 69.63.8
Fat mass, kg 17.42.5 22.51.9 17.92.6 22.92.4
Body fat, % 28.73.0 33.52.0 29.92.9 33.52.4
Fat-free mass, kg 41.31.2 44.72.5 40.51.3 45.02.6
Appendicular fat-free mass, kg 17.60.6 19.21.2 17.20.6 19.51.2
Total abdominal fat area, cm2 24345 29935 25345 30337
Subcutaneous abdominal fat area, cm2 19442 24933 19943 25136
Intra-abdominal fat area, cm2 484 507 546 527
Mid-thigh fat area, cm2 11318 15322 12724 15024
Midthigh muscle area, cm2 1116 11810 1076 11611
Data are means  SE. Baseline data represent the average of follicular and luteal phase evaluations. Sample sizes are n  7 and n  6 for
gonadotropin-releasing hormone agonist (GnRHa) and placebo groups, respectively, except for midthigh tissue composition data, where sample sizes are n 
6 and n  5, respectively.
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under the curve for the first-phase insulin-secretory response in
the luteal vs. the follicular phase of the cycle (F: 3,957  554
vs. L: 4,420  570 pmol/m2, P  0.01) but no cycle effect on
the area under the curve of second-phase insulin secretion (F:
47,667  6,243 vs. L: 48,956  4,849 pmol/m2, P  0.552).
Because of these cycle-dependent differences, in analyses
below, we also examined the effect of GnRHa treatment by
comparing posttreatment data to baseline follicular and luteal
phase evaluations individually. No effect of cycle phase was
found on insulin clearance (F: 1.74  0.19 vs. L: 1.63  0.13
l min1 m2; P  0.33; data not shown in Fig. 2).
Pre- and posttreatment glucose (top), insulin (middle) and
C-peptide (bottom) levels during the hyperglycemic clamp are
shown in Fig. 3 for GnRHa and placebo groups. There were no
Fig. 2. Glucose disposal index (A), insulin secretion (B), and first- and second-
phase insulin-secretory response (C) during follicular (closed bar/symbols) and
luteal (open bar/symbols) phase evaluations (n  13). Total glucose disposal data
represent the average glucose infusion rate during the last 30 min of the clamp plus
residual endogenous glucose disposal derived from [2H2]glucose kinetics and are
expressed relative to the average insulin level during the same period. Total
glucose disposal was divided into nonoxidative (Non-ox) and oxidative (Ox)
disposal pathways. Non-ox was calculated as the difference between total glucose
disposal and Ox disposal measured using the [13C6]glucose tracer. For Non-ox and
Ox disposal data, n  12 due to the absence of indirect calorimetry data in 2
patients. Insulin-secretory dynamics are calculated from plasma insulin and C-
peptide levels, as described in MATERIALS AND METHODS. Area under the curve
(AUC) was calculated for 1st-phase (120–128 min) and 2nd-phase (128–240 min)
insulin-secretory responses. Data are means  SE. *P  0.02.
Fig. 1. Plasma glucose, insulin, and C-peptide levels during the hyperglycemic
clamp for follicular () and luteal (‚) phases evaluations (n  13). Data are
means  SE.
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group  time interaction effects noted for fasting plasma
glucose (GnRHa 75  2 to 76  1 vs. placebo 77  1 to 75 
2 mg/dl, P  0.298), insulin (GnRHa 10  1 to 11  2 vs.
placebo 8  1 to 10  2 U/mL; P  0.677), C-peptide
(GnRHa 1.9  0.4 to 1.9  0.3 vs. placebo 1.7  0.1 to 1.7 
0.2 ng/ml, P  0.887) or mean plasma glucose level during the
last 30 min of the clamp (GnRHa 194  1 to 195  2 vs.
placebo 194  5 to 187  6 mg/dl, P  0.238).
The effect of ovarian suppression on glucose disposal is
shown in Fig. 4. No group  time interaction effects were
noted for total [GnRHa 11.7  2.5 to 13.4  2.7 vs. placebo
12.2  2.5 to 13.7  3.4 (mg/min)/(U/ml), P  0.863],
oxidative [GnRHa 1.36  0.25 to 1.23  0.25 vs. placebo
1.76  0.38 to 1.68  0.43 (mg/min)/(U/mL), P  0.783] or
nonoxidative [GnRHa 10.1  2.3 to 12.2  2.5 vs. placebo
10.5  2.2 to 12.0  3.0 (mg/min)/(U/ml), P  0.756]
glucose disposal expressed relative to plasma insulin level.
Similarly, there were no group  time interaction effects for
residual endogenous glucose production [GnRHa 0.33  0.22
to 0.21  0.18 vs. placebo 0.44  0.20 to 0.54  0.31
(mg/min)/(U/ml), P  0.514; data not shown in Fig. 4]. No
group  time interaction effects were found for any glucose
disposal data when posttreatment data were compared with
either follicular or luteal phase measurements individually
(range of P values 0.459 to 0.960). Finally, no group  time
interaction effects were noted when glucose disposal data were
expressed relative to body mass or fat-free mass (data not
shown).
The effect of GnRHa administration on insulin secretion,
first- and second-phase insulin-secretory responses, and insulin
clearance are shown in Fig. 5. No group  time interaction
effect was found for the area under the curve for the first-phase
(GnRHa 4,745  866 to 4,497  849 vs. placebo 3,539  639
to 3,687  724 pmol/m2, P  0.201) or second-phase (GnRHa
54,327  9,412 to 54,286  8,081 vs. placebo 41,294  3,802
Fig. 3. Plasma glucose, insulin, and C-peptide levels during the hyperglycemic
clamp in GnRHa (circles; n  7) and placebo (squares; n  6) for baseline
(open symbols) and posttreatment (closed symbols) evaluations. Data are
means  SE.
Fig. 4. Glucose disposal index (A), insulin secretion (B), and insulin clearance
(C) data in GnRHa (n  7) and placebo (n  6) groups for baseline (closed
bar/symbols) evaluations. Total glucose disposal data represent the average
glucose infusion rate during the last 30 min of the clamp plus residual
endogenous glucose disposal derived from [2H2]glucose kinetics and are
expressed relative to the average insulin level during the same period. Total
glucose disposal during this period was divided into Non-ox and Ox disposal
pathways. Non-ox was calculated as the difference between total glucose
disposal and Ox disposal measured using the [13C6]glucose tracer. Data are
means  SE.
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to 43,905  2,905 pmol/m2, P  0.485) insulin-secretory
response or insulin clearance rates (GnRHa 1.67  0.16 to
1.87  0.15 vs. placebo 1.76  0.29 to 2.00  0.38
l min1 m2, P  0.807). Because there were menstrual cycle
differences in the first-phase insulin-secretory response, we
also examined the effect of GnRHa administration by compar-
ing the individual menstrual cycle phases to the posttreatment
evaluation. However, there was still no group  time interac-
tion effect noted for first-phase insulin secretion when post-
treatment data were compared with either follicular (P 
0.170) or luteal (P  0.385) phases individually.
The effects of the menstrual cycle and GnRHa treatment
on circulating adipokine levels are shown in Fig. 6. No
effect of menstrual cycle phase was found on circulating
adiponectin (F: 9.54  1.41 vs. L: 10.58  1.98 g/ml, P 
0.269), although a trend toward greater leptin level was
observed in the luteal phase (F: 16.00  3.06 vs. L: 18.91 
3.02 ng/ml, P  0.09). A significant group  time interac-
tion effect was observed for adiponectin (P  0.01). Further
examination of simple effects showed no change in adi-
ponectin in the placebo group (Pre 9.84  2.17 vs. Post
Fig. 6. Effect of menstrual cycle phase (A) and GnRHa administration (B and
C) on circulating adipokine levels. For all measurements, total sample size is
n  13, with n  7 for the GnRHa group and n  6 for the placebo group.
A: follicular phase evaluations are shown as closed bars and luteal phase as
open bars. B and C: baselines are represented by open bars and posttreatment
by closed bars. Data are means  SE. *P  0.01 group  time interaction
effect, P  0.001 simple effect of time within the GnRHa group.
Fig. 5. Insulin secretion (A and B) and clearance (C) data in gonadotropin-
releasing hormone agonist (GnRHa; n  7) and placebo (n  6) groups for
baseline (open bars/symbols) and posttreatment (closed bars/symbols) evalu-
ations. Insulin secretion data are calculated from plasma C-peptide levels, as
described in MATERIALS AND METHODS. AUC was calculated for 1st-phase
(120–128 min) and 2nd-phase (128–240 min) insulin-secretory responses.
Insulin clearance was calculated as the ratio of insulin secretion rate to the
corresponding plasma insulin concentration from 140 to 240 min and is
expressed as the mean of the ratios at each time point. Data are means  SE.
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8.80  1.80 g/ml, P  0.154) but a significant increase in
the GnRHa group (Pre 10.25  2.61 vs. Post 12.94  2.97
g/ml; P  0.001). No group  time interaction effect was
observed (P  0.786) for leptin when average baseline-to-
posttreatment values were compared (GnRHa 14.86  3.84
to 14.79  4.67 ng/ml; placebo 20.58  4.54 to 19.96 
4.55 ng/ml) or when follicular or luteal phase evaluations
were compared with the posttreatment evaluation individu-
ally (P  0.733 and 0.959, respectively).
DISCUSSION
To examine the physiological role of ovarian hormones in
the regulation of glucose homeostasis, we measured glucose
disposal index and insulin secretion in young, healthy, eugo-
nadal women before and after pharmacological suppression of
ovarian hormone production with GnRHa. To our knowledge,
this is the first study to evaluate, using a randomized, con-
trolled design, the effects of GnRHa treatment on glucose
disposal and insulin secretion in healthy, young women with
normal menstrual cyclicity. We hypothesized that ovarian
suppression would reduce both glucose disposal and insulin
secretion. Contrary to this hypothesis, however, we found no
effect of 2 mo of GnRHa treatment, and the resulting ovarian
hormone-deficient state, on either glucose disposal or insulin
dynamics in healthy eugonadal women.
GnRHa treatment did not affect glucose disposal index in
response to the hyperglycemic clamp stimulus. Our data agree
with studies examining the effects of GnRHa on glucose
disposal in healthy obese women evaluated using variable
hyperglycemic hyperinsulinemic clamps (15) and in healthy
lean women assessed by oral and intravenous glucose tolerance
tests (3). Taken together with our prior results using the
hyperinsulinemic clamp (7), these findings suggest that ovarian
hormone suppression with GnRHa does not modulate tissue
responsiveness to insulin (7) or to the combined effects of
insulin and hyperglycemia (3, 15).
Subtle changes in the intracellular pathways of glucose
disposal might not be discerned from measurements of total
glucose disposal. This is particularly important in the context
of ovarian hormones, since animal models have shown that
hormone deficiency specifically reduces nonoxidative glucose
disposal (27, 40). Thus, we partitioned total glucose disposal
into oxidative and nonoxidative components by use of a com-
bination of stable isotope-labeled glucose ([U-13C]glucose)
and indirect calorimetry. Similar to total glucose disposal,
however, we found no effect of GnRHa on either oxidative or
nonoxidative glucose disposal. The reason for disparities be-
tween data from humans and those from animal models is not
clear. The effect of ovarian hormones in animals may relate to
an indirect effect of ovarian hormone deficiency to induce
hyperphagia and, in turn, increase adiposity (39), which would
be expected to reduce nonoxidative glucose disposal (28). In
contrast, GnRHa treatment in the present study did not alter
body weight, adiposity or fat distribution (Table 1), and food
intake was controlled for 3 days prior to glucose disposal
measurements to eliminate any effects of GnRHa treatment on
the antecedent diet. Thus, our results are likely unaffected by
either acute or chronic alterations in energy balance. Together
with our results using the hyperinsulinemic clamp (7), the
current data provide further evidence that a brief period of
ovarian hormone deficiency does not alter intracellular path-
ways of glucose disposal in humans.
GnRHa treatment did not alter first- or second-phase insulin
secretion or insulin clearance. To our knowledge, this is the
first study to directly examine the effect of GnRHa treatment
on insulin secretion in humans by using a controlled hypergly-
cemic stimulus. Our results agree with those of Cagnacci et al.
(3), who found no effect of 1 mo of GnRHa treatment on
plasma insulin and C-peptide responses to either oral or intra-
venous glucose loads in women. Thus, in healthy women a
brief period of ovarian suppression with GnRHa does not
modulate insulin dynamics in response to either oral or intra-
venous glucose administration.
An important caveat to the present study and others (3, 7, 15)
that have used the GnRHa model is that treatment is associated
with mild reductions in circulating total and free testosterone,
as well as androgenic precursors (Table 2). This complicates
the interpretation of our findings if androgens regulate glucose
homeostasis. Although pharmacological doses of androgens have
minimal effects on insulin secretion, they have been shown to
impair glucose disposal in women (11), and endogenous hyperan-
drogenemia is associated with insulin resistance (16). Moreover,
in cross-sectional studies of eugonadal women, variation in serum
total and free testosterone within the physiological range is
negatively correlated with plasma insulin response during hy-
perglycemic clamps (22). Thus, one could postulate that our
hypothesized effect of GnRHa treatment to reduce glucose
disposal and insulin secretion could be masked by a reciprocal
effect of reduced androgen levels to enhance these parameters.
Although this scenario is plausible, it is unclear what effect, if
any, a reduction in circulating levels of androgens might have
on glucoregulation in women with normal androgen levels. In
men, GnRHa treatment impairs glucose disposal under hyper-
glycemic clamp conditions but has minimal effects on insulin
secretion (5). Normal circulating testosterone levels are signif-
icantly greater in men, and their decline in response to GnRHa
(400 ng/dl) is 20-fold higher than that observed in women in
the present study (18 ng/dl). The question then becomes
whether such small reductions in testosterone affect glucose
disposal and insulin secretion in euandrogenemic women.
Preliminary studies from our laboratory have shown, contrary
to pharmacological and pathological hyperandrogenemia, that
circulating androgens within the physiological range are posi-
tively associated with insulin-stimulated glucose disposal in
postmenopausal women (Casson PR, unpublished observa-
tions), whereas other studies have shown no relationship
between androgen levels and glucose disposal in young
eugonadal women (22). Thus, rather than masking an effect of
ovarian hormone deficiency on glucose disposal, GnRHa-
induced reductions in testosterone levels may have no effect or
could even enhance the suppressive effects of GnRHa treat-
ment on glucose disposal. With respect to insulin secretion,
although some studies have shown modest negative correla-
tions between androgen levels and insulin secretion in eugo-
nadal women (22), pharmacological administration of andro-
gens to women has no effect on insulin secretion (11). More-
over, GnRHa treatment in men does not alter plasma insulin
response to the hyperglycemic clamp stimulus (5). On the basis
of these data, we believe that androgen levels probably had
minimal effects on insulin secretion.
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Our results regarding the effect of menstrual cycle phase on
glucose metabolism deserve further comment. That menstrual
cycle phase did not affect glucose disposal index is at odds
with the only other study to use the hyperglycemic clamp to
investigate cycle effects on glucose homeostasis, which found
reduced glucose disposal during the luteal phase (13). The fact
that studies using the hyperinsulinemic clamp from both lab-
oratories (7, 12), as well as others (46, 59), show no effect of
menstrual cycle phase on insulin-stimulated glucose disposal
suggests that reduced glucose disposal in the luteal phase
observed with the hyperglycemic clamp (12) may due to a
diminished ability of hyperglycemia to stimulate glucose dis-
posal (i.e., glucose-induced glucose disposal). Unfortunately,
no study has directly measured the effect of ovarian hormones
on glucose-induced glucose disposal. One study that attempted
to experimentally reproduce luteal phase estradiol and proges-
terone levels by administration of oral micronized estradiol and
progesterone failed to find an effect of either hormone alone or
in combination on glucose disposal measured under euglyce-
mic and hyperinsulinemic conditions (45), suggesting no effect
of these hormones on glucose-induced glucose disposal. Thus,
reasons to explain differences between the two studies are not
readily apparent. The only notable differences are that the
present study had a larger sample size (13 vs. 8) and controlled
dietary intake for 3 days prior to the hyperglycemic clamps.
With respect to the latter point, the luteal phase of the men-
strual cycle is associated with increased energy intake and
expenditure (2, 32). If intake exceeds expenditure during the
luteal phase, this could result in a brief period of overfeeding
that could impair glucose disposal. That this may occur is
buttressed by the fact that women are susceptible to impaired
glucoregulation in response to short-term energy excess (9).
Thus, our attempt to control food intake prior to measurements
could have diminished or prevented luteal phase hyperphagia
and any corresponding reductions in glucose disposal second-
ary to energy imbalance. Perhaps most importantly, the ab-
sence of reduced glucose disposal index during the luteal phase
would not impair our ability to detect an effect of GnRHa on
glucose disposal. If anything, the absence of menstrual cycle
differences in glucose disposal would enhance, not hinder, our
ability to detect an effect of GnRHa.
In addition, we observed a small, but significant, increase in
the first-phase insulin secretion during the luteal phase. Al-
though to our knowledge no other study has measured insulin
secretion rate during the menstrual cycle, our findings differ
slightly from other studies that have failed to show altered
plasma insulin levels in response to intravenous glucose (13,
38). Some studies have shown cycle-dependent differences in
plasma insulin responses that were similar in magnitude to
those in our study (38), albeit nonsignificant. Additionally,
another study that attempted to experimentally reproduce luteal
phase estradiol and progesterone levels by administration of
oral micronized estradiol and progesterone found a similar
magnitude increase in plasma insulin response to the hyper-
glycemic clamp (45). Importantly, we should stress that com-
parison of posttreatment insulin dynamics data to either base-
line follicular or luteal phase measurements separately did not
reveal an effect of GnRHa, suggesting that any cycle-depen-
dent differences in insulin secretion would not impact the
overall conclusions of our study.
A novel result in this study was the increase in plasma
adiponectin in women treated with GnRHa. The fact that
adiponectin increased in response to GnRHa-induced ovarian
suppression is in keeping with cross-sectional data showing a
negative relationship between estradiol and adiponectin (20) but
contrasts with studies showing that transdermal estradiol increases
adiponectin in obese postmenopausal women with the metabolic
syndrome (6). We should note that, as with glucose metabo-
lism, modest decreases in testosterone with GnRHa adminis-
tration confound the interpretation of our results. Because
testosterone decreases circulating adiponectin levels (34, 35,
58), the reduction in circulating testosterone in response to
GnRHa could increase adiponectin (35, 58). These inhibitory
effects of testosterone on adiponectin, however, have been
observed in men, where changes in testosterone (35, 58) are
considerably greater than those observed in the present study.
If we assume that androgen receptors are present in adipocytes
at similar levels in men and women (14) and have similar
binding affinities, it seems unlikely that such small changes in
androgen levels in women would provoke the observed
changes in adiponectin.
Regardless of the hormonal mediator, as adiponectin is
believed to sensitize tissues to the effects of insulin, it could be
argued that the increase in adiponectin diminished the effect of
GnRHa treatment to impair glucose disposal. The relative
change in adiponectin in our study, however, was quite modest
compared with alterations previously demonstrated to correlate
to altered tissue insulin responsiveness (36). Moreover, the
effect of adiponectin is thought to derive from alterations in
hepatic insulin sensitivity (33, 36), whereas we found no
alterations in the suppression of endogenous glucose produc-
tion with GnRHa, an index of hepatic insulin sensitivity. Thus,
we think that it is unlikely that changes in adiponectin influ-
enced glucose disposal data.
Our study is limited by small samples sizes. The direction-
ality of some of the observed changes in glucose disposal and
insulin secretion, however, were not in accord with our hy-
potheses. In these instances, our data clearly argue against the
notion that ovarian hormone deficiency is of importance for the
pathogenesis of glucose intolerance with age. For other vari-
ables, such as first-phase insulin secretion, the number of
volunteers needed to detect a group  time interaction effect
concordant with our hypothesis is quite large (50 per group).
In these cases, the question then becomes whether such small
changes in outcome variables are physiologically or patho-
physiolgically relevant. In other words, if suppression of ovar-
ian hormone concentrations to postmenopausal levels with
GnRHa invokes such minor changes in glucose disposal or
insulin secretion, one might conclude simply that the hormones
play a relatively minor role in the regulation of glucose/insulin
homeostasis.
In summary, our study suggests that 2 mo of ovarian hor-
mone deficiency induced by GnRHa administration has no
effect on glucose disposal or insulin dynamics. Although we
acknowledge the limitation of extrapolating our findings using
GnRHa in young eugonadal women to middle-aged women
transitioning to the menopausal state, from a physiological
perspective, our data suggest a minor role for endogenous
ovarian hormones in the regulation of glucose disposal or
insulin secretion. Similarly, we should note that our results are
limited to eugonadal women, and the lack of effect of GnRHa
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on glucose metabolism and insulin secretion may not apply to
other populations, such as hyperandrogenic women. Our find-
ings do, however, suggest a potential role for ovarian hormones
in the regulation of plasma adiponectin levels.
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